PT Kalbe Farma Tbk (KLBF) recorded a net profit attributable to owners of the parent entity of Rp2.63 trillion in Q3 2025.
This net profit increased by 10.63% from Rp2.37 trillion in the same period last year (year-on-year/yoy).
In line with this, KLBF's sales grew by 7.21% (yoy) to Rp25.98 trillion in the third quarter of this year.
This performance growth was supported by domestic sales of Rp24.13 trillion, an increase of 5.31% (yoy), and export sales of Rp1.85 trillion, which surged by 40.15% (yoy).
These sales covered segments such as prescription drugs, health products, nutrition, and distribution and logistics.
"Various strategic initiatives such as the oncology ecosystem, the development of biological drugs and medical devices are proceeding as planned, and we continue to rejuvenate brands in consumer product categories to remain relevant with current consumer trends," said Irawati Setiady, President Director of PT Kalbe Farma Tbk, in her statement on Monday, October 27, 2025.
In addition, the company also focuses on providing good total shareholder return, supported by fundamental performance and dividend policy.
As of the end of September 2025, KLBF had assets valued at Rp30.10 trillion. This value increased by 2.28% from Rp29.42 trillion at the end of December 2024.